Latest Conference Articles

Results from the phase 3 EVEREST trial presented during the 2022 ASCO Annual Meeting reveal the relapse-free survival advantage of using adjuvant everolimus over placebo in patient with high-risk renal cell carcinoma.

According to new COSMIC-021 data, atezolizumab combined with cabozantinib may be active in patients with urothelial carcinoma.

Reductions in severe oral mucositis across all intensity-modulated radiotherapy landmarks was observed with avasopasem treatment in patients with locally advanced, nonmetastatic head and neck cancer.

Therapy with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, in patients with previously untreated stage III/IV classical Hodgkin lymphoma.

Treatment with the KRAS G12C inhibitor adagrasib showed a promising objective response rate and disease control rate in patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

The use of pembrolizumab plus ramucirumab to treat non–small cell lung cancer in immune checkpoint inhibitor resistant patients showed better overall survival versus standard of care regimens in the Lung-MAP nonmatched phase 2 substudy S1800A.

Treatment with sugemalimab shown to be well-tolerated and have a consistent safety profile to other studies, according to results of the GEMSTONE-201 trial.

Karen L. Reckamp, MD, explains the need for more treatment options for patients with non–small cell lung cancer who have been previously treated with immune checkpoint inhibitors and develop resistance.

The combination of nimotuzumab and gemcitabine extended overall survival in patients with KRAS wild-type advanced pancreatic cancer, especially in those who did not need surgery for obstruction of a pancreatic bile duct

According to a survey, some Black patients with metastatic breast cancer harbor distrust toward clinical trials, which has impacted the number of Black patients who participate.

After identifying a survival disparity among non-White Hispanic patients with pediatric neuroblastoma, investigators will next examine the interaction of survival and race, ethnicity, and poverty, acknowledging the intersectionality of these factors due to structural racism in the United States.

The combination of tislelizumab plus nab-paclitaxel demonstrated benefit and a tolerable safety profile in patients with high-risk non–muscle invasive bladder cancer.

Tislelizumab plus nab-paclitaxel as neoadjuvant treatment demonstrated benefit with a high rate of pathologic complete response in patients with muscle-invasive bladder cancer.

Both TROP-2 and Nectin-4 were shown to be highly expressed in urothelial cancer and variant histology bladder cancer, but not in patients with neuroendocrine histology.

IS-002 was shown to be safe, well-tolerated, and allow for enhanced intraoperative tumor detection in patients undergoing robotic prostatectomy, according to findings from a phase 1 study.

Health-related quality-of-life outcomes were maintained among patients with low grade non-muscle invasive bladder cancer who were treated with UGN-102, a chemoablative reverse thermal gel as a primary approach in the single-arm phase 2b Optima II trial.

Interim results from a biomarker-informed preoperative study of infigratinib demonstrated substantial activity and tolerability in patients with localized upper tract urothelial carcinoma, according to findings of a phase 1b trial.

Roger Li, MD, shares the results of the phase 2 CORE1 clinical trial, which evaluated CG0070 in combination with pembrolizumab for the treatment of patients with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.

Neoadjuvant axitnib demonstrated significant reductions in tumor size and complexity, allowing for partial nephrectomy in a subgroup of patients with renal cell carcinoma.

Darolutamide plus androgen deprivation therapy and docetaxel was not associated with an increase in incidence or severity of adverse events versus androgen deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Chemotherapy plus intravenous vitamin C shows benefit in cisplatin-ineligible patients with locally advanced muscle-invasive bladder cancer.

Data supporting prostate-specific antigen screening shows harm-benefit tradeoff to be more favorable with complementary approaches to quantifying overdiagnosis.

The safety profile of relugolix in patients with advanced prostate cancer has been demonstrated in the phase 3 HERO clinical trial.

Long-term follow-up results from the JAVELIN Bladder 100 study further support the standard-of-care role of avelumab as frontline maintenance in patients with urothelial carcinoma.

Results from a post-hoc analysis of ARCHES showed that the enzalutamide plus ADT significantly improved survival, as well as key secondary end points, compared with placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Findings from a post-hoc analysis of the phase 3 ARAMIS clinical trial shows positive efficacy and consistent safety and tolerability with darolutamide in patients with nonmetastatic castration resistant prostate cancer, despite type of prior local therapy.

In patients with high-risk, muscle-invasive urothelial carcinoma treated in the adjuvant nivolumab lead to clinically meaningful improvements in disease-free survival compared with placebo.

Neal Shore, MD, FACS discusses results from a post-hoc analysis of the phase 3 ARCHES trial.

Use of 18F-rhPSMA-7.3 PET results in post-scan upstaging compared with conventional imaging in patients with prostate cancer recurrence.